Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NeuroPace IncNPCE · Entity 5459 | 10% owner | February 20, 2025 | February 20, 2025 |
| Sight Sciences, Inc.SGHT · Entity 5537 | 10% owner | July 19, 2021 | July 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NeuroPace Inc
Report date February 20, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-20 transaction · row 1
1 source rowRow 1 · 2025-02-20 · Sale · Disposed 5,270,845 · Balance 0 |
Sight Sciences, Inc.
Report date July 19, 2021 · Filed July 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,776,232 |
Reported balance
After 2021-07-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-19 · Conversion · Acquired 4,776,232 · Balance 4,776,232 F1: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-19 · Conversion · Disposed 2,388,116 · Balance 0 F1: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Rein Therapeutics, Inc.
Report date July 05, 2017 · Filed July 06, 2017
Section 16 reporting ended · disclosed 2017-07-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 646,817 |
Ending reported balance
After 2017-07-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-07-05 · Conversion · Acquired 446,817 · Balance 446,817 F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Row 2 · 2017-07-05 · Purchase · Acquired 200,000 · Balance 646,817 |
| Series E-3 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-07-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-07-05 · Conversion · Disposed 3,676,471 · Balance 0 F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Series F Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-07-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-07-05 · Conversion · Disposed 763,552 · Balance 0 F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2025 Filed Feb 20, 2025 14:51 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 5,270,845 | $9.40 | $49,545,943.00 |
DisclosureSEC source: 0001657662-25-000003 · primary_doc.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 19:49 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 223,991 | $5.45 | $1,221,042.14 |
DisclosureSEC source: 0001657662-24-000007 · primary_doc.xml · nonDerivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,270,845 Read SEC document |
| October 23, 2024 Filed Oct 28, 2024 19:49 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 147 | $6.02 | $884.94 |
DisclosureSEC source: 0001657662-24-000007 · primary_doc.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,494,836 Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 18:23 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,082 | $6.09 | $24,853.26 |
DisclosureSEC source: 0001657662-24-000006 · primary_doc.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,494,983 Read SEC document |
| October 21, 2024 Filed Oct 22, 2024 14:35 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,720 | $6.10 | $22,678.61 |
DisclosureSEC source: 0001657662-24-000005 · primary_doc.xml · nonDerivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,499,065 Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 14:35 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,878 | $6.29 | $30,691.89 |
DisclosureSEC source: 0001657662-24-000005 · primary_doc.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,502,785 Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,294 | $6.28 | $20,686.32 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 11 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,507,663 Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 6,900 | $6.57 | $45,336.45 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 10 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,510,957 Read SEC document |
| October 15, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,017 | $6.50 | $26,098.45 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 9 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,517,857 Read SEC document |
| October 14, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,031 | $6.54 | $26,359.92 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 8 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,521,874 Read SEC document |
| October 11, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 2,572 | $6.35 | $16,319.60 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 7 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,525,905 Read SEC document |
| October 10, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 2,504 | $6.12 | $15,316.97 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 6 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,528,477 Read SEC document |
| October 09, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,123 | $6.10 | $19,065.29 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 5 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,530,981 Read SEC document |
| October 08, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 6,000 | $6.43 | $38,551.80 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 4 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,534,104 Read SEC document |
| October 07, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,910 | $6.66 | $32,687.34 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 3 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,540,104 Read SEC document |
| October 04, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 5,757 | $6.92 | $39,829.80 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,545,014 Read SEC document |
| October 03, 2024 Filed Oct 18, 2024 14:17 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,318 | $6.97 | $23,114.85 |
DisclosureSEC source: 0001657662-24-000004 · primary_doc.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,550,771 Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,843 | $6.87 | $26,401.41 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 13 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,554,089 Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,882 | $6.77 | $33,051.14 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 12 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,557,932 Read SEC document |
| September 30, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,749 | $6.73 | $31,960.77 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 11 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,562,814 Read SEC document |
| September 27, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 5,059 | $6.63 | $33,541.17 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 10 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,567,563 Read SEC document |
| September 26, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 5,821 | $6.62 | $38,535.02 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 9 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,572,622 Read SEC document |
| September 25, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 5,858 | $6.60 | $38,662.80 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 8 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,578,443 Read SEC document |
| September 23, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 282 | $7.54 | $2,126.28 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 7 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,584,301 Read SEC document |
| September 20, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 765 | $7.50 | $5,737.50 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 6 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,584,583 Read SEC document |
| September 13, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 1,993 | $7.59 | $15,126.87 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 5 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,585,348 Read SEC document |
| September 06, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 11 | $7.50 | $82.50 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 4 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,587,341 Read SEC document |
| September 04, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 14 | $7.50 | $105.00 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 3 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,587,352 Read SEC document |
| September 03, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 2,093 | $7.60 | $15,906.80 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,587,366 Read SEC document |
| August 30, 2024 Filed Oct 3, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,314 | $7.76 | $33,476.64 |
DisclosureSEC source: 0001062993-24-017384 · form4.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,589,459 Read SEC document |
| December 01, 2023 Filed Dec 2, 2023 02:57 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,241 | $8.73 | $28,293.93 |
DisclosureSEC source: 0001062993-23-021754 · form4.xml · nonDerivative · entry 3 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,593,773 Read SEC document |
| November 30, 2023 Filed Dec 2, 2023 02:57 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 7,282 | $8.84 | $64,372.88 |
DisclosureSEC source: 0001062993-23-021754 · form4.xml · nonDerivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,597,014 Read SEC document |
| November 29, 2023 Filed Dec 2, 2023 02:57 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 5,644 | $8.72 | $49,215.68 |
DisclosureSEC source: 0001062993-23-021754 · form4.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,604,296 Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 22:35 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 4,681 | $8.75 | $40,958.75 |
DisclosureSEC source: 0000950170-23-066847 · ownership.xml · nonDerivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,609,940 Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 22:35 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 6,490 | $8.96 | $58,150.40 |
DisclosureSEC source: 0000950170-23-066847 · ownership.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,614,621 Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 22:35 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | ConversionSeries D Convertible Preferred Stock · Derivative | 2,388,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006636 · form4.xml · derivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,776,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date. F1 · derivative.exercise_date: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date. F1 · derivative.expiration_date: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 22:35 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | ConversionCommon Stock | 4,776,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-006636 · form4.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,776,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date. F1 · price: Reflects automatic conversion of Series D Convertible Preferred Stock into common stock on a 2 for 1 basis upon the closing of the initial public offering of Issuer's common stock. The shares have no expiration date. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:14 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionSeries B' Prime Preferred Stock · Derivative | 5,271,902 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028321 · doc4.xml · derivative · entry 3 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,271,902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:14 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionSeries A' Prime Preferred Stock · Derivative | 323,591 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028321 · doc4.xml · derivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 323,591 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:14 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionCommon Stock | 5,595,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028321 · doc4.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,621,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 00:28 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries F Preferred Stock · Derivative | 763,552 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017899 · doc4.xml · derivative · entry 4 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 00:28 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries E-3 Preferred Stock · Derivative | 3,676,471 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017899 · doc4.xml · derivative · entry 3 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 369,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 00:28 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0000899243-17-017899 · doc4.xml · nonDerivative · entry 2 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,817 Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 00:28 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionCommon Stock | 446,817 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-017899 · doc4.xml · nonDerivative · entry 1 KCK LTD. · CIK 0001657662 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.